Cell Microsystems Acquires Fluxion Biosciences

Solidion Technology Pursues Acquisition of Flux Power After Flux Board Rejected Offer

October 5, 2026

Energy

Solidion Technology responded to Flux Power Holding’s board decision to reject Solidion’s previously announced acquisition proposal, stating it views its bid as “best and final.” Solidion argues Flux faces capital needs and other risks, and believes acquisition by a stronger balance-sheet company is the clearer path versus a highly dilutive turnaround.

Continuity Biosciences Acquires Focal Medical

June 4, 2025

Biotechnology

Continuity Biosciences, LLC has acquired Focal Medical, Inc., a North Carolina–based biopharmaceutical company developing iontophoresis-based, site-specific chemotherapy delivery for pancreatic cancer. The acquisition transfers Focal Medical's patent estate, device platform, equipment, licensing agreements and key personnel to Continuity as it expands its drug‑delivery and device-enabled therapeutics capabilities and advances the lead program toward clinical trials.

Illumina Acquires Fluent BioSciences

July 9, 2024

Biotechnology

Illumina, Inc. has acquired Fluent BioSciences to integrate Fluent's PIPseq single-cell technology into Illumina's product portfolio and accelerate its multiomics capabilities. The acquisition, which closed July 9, 2024 and was funded with cash on hand, brings Fluent's accessible, scalable single-cell chemistry and the Fluent team into Illumina to expand end-to-end single-cell solutions for research and applied customers.

Leica Biosystems Acquires Cell IDx

November 8, 2022

Biotechnology

Leica Biosystems has acquired Cell IDx, a San Diego-based leader in multiplexed tissue profiling, integrating Cell IDx's UltraPlex multiplex IHC technology with Leica's BOND RX automation to expand translational research and multiplexing capabilities. The deal advances Leica's research-focused staining and imaging portfolio and brings scale-up and medical/scientific affairs support for Cell IDx customers.

Emerson Acquires Fluxa (after earlier equity investment)

February 25, 2021

Software

Emerson (NYSE: EMR) initially made an equity investment in Fluxa in February 2021 to accelerate the development and commercialization of Fluxa’s Process & Knowledge Management (PKM) life‑sciences software. Emerson later completed a full acquisition of Fluxa (announced June 30, 2022) to integrate Fluxa’s PKM capabilities with Emerson’s life‑sciences automation and execution systems.

IDEX Corporation Acquires Microfluidics International Corporation

January 11, 2011

Medical Devices

IDEX Corporation agreed to acquire Microfluidics International Corporation in an all-cash transaction valued at $1.35 per share, expected to close in Q1 2011. The acquisition adds Microfluidics' Microfluidizer high-shear fluid processors and nanomaterials processing capabilities to IDEX's Fluid and Metering segment to expand its pharmaceutical and particle-processing product offerings.